Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Azithromycin vs placebo or standard of care alone Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 1.11 [0.89, 1.4] | 4 studies · 794 participants | Moderate |
Azithromycin vs placebo or standard of care alone Any adverse events during the study period · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 1.2 [0.92, 1.57] | 3 studies · 355 participants | Low |
Azithromycin vs placebo or standard of care alone Cardiac arrhythmias during the study period · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 0.92 [0.73, 1.15] | 4 studies · 7865 participants | Moderate |
Azithromycin vs placebo or standard of care alone All‐cause mortality at day 28 · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 1 [0.06, 15.69] | 3 studies · 876 participants | Low |
Azithromycin vs placebo or standard of care alone Admission to hospital or death within 28 days · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 0.94 [0.57, 1.56] | 3 studies · 876 participants | Low |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone All‐cause mortality at hospital discharge · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | 2 studies · 313 participants | Very low |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Improvement of clinical status · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Worsening of clinical status · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | RR 0.52 [0.24, 1.13] | 1 study · 237 participants | Low |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Quality of life, including fatigue and neurological status · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Adverse events (any grade) · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | RR 2.98 [0.12, 72.3] | 1 study · 237 participants | Very low |
Summary of Findings Table ‐ Vitamin D vs placebo or standard care alone Serious adverse events · individualswith moderate to severe disease Vitamin D supplementation for the treatment of COVID‐19: a living systematic review (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus standard care vs standard care (plus/minus placebo) All‐cause mortality assessed up to day 28 · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 2 studies · 11445 participants | Moderate |
Colchicine vs placebo or standard care alone Duration to symptom resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs placebo or standard care alone Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs placebo or standard care alone Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 4412 participants | Low |
Colchicine vs placebo or standard care alone Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 4412 participants | Moderate |
Colchicine plus standard care vs standard care (plus/minus placebo) Worsening of clinical status: participants with clinical deterioration, defined as new need for invasive mechanical ventilation or death up to day 28 · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 2 studies · 10916 participants | Moderate |
Colchicine plus standard care vs standard care (plus/minus placebo) Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 11340 participants | Moderate |
Colchicine plus standard care vs standard care (plus/minus placebo) Quality of life, including fatigue and neurological status at longest · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus standard care vs standard care (plus/minus placebo) Adverse events ( · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 72 participants | Very low |
Colchicine plus standard care vs standard care (plus/minus placebo) Serious adverse events ( · people with COVID‐19 and moderate to severe disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 105 participants | Very low |
Colchicine vs placebo or standard care alone All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 4488 participants | Low |
Colchicine vs placebo or standard care alone Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 1 study · 4488 participants | Moderate |
Colchicine vs placebo or standard care alone Symptom resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease Colchicine for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | HR 5.09 [2.64, 9.81] | 9 studies · 1802 participants | Moderate |
Intervention NR Progression‐free survival · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | HR 4.9 [3.47, 6.9] | 14 studies · 2079 participants | Very low |
Intervention NR Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival (adjusted effect estimate) · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | no estimate extracted | 2 studies · 843 participants | Moderate |
Intervention NR Progression‐free survival (adjusted effect estimate) · Individuals with Hodgkin lymphoma Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of… (2020) · Cochrane | no estimate extracted | 4 studies · 996 participants | Low |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates All‐cause mortality ‐ Intention‐to‐treat analysis · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | RR 0.55 [0.26, 1.19] | 1 study · 40 participants | Very low |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | 1 study · 224 participants | Ungraded |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Thrombosis‐related mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Asymptomatic venous thromboembolism ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates First‐time symptomatic venous thromboembolism · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | 1 study · 40 participants | Ungraded |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Major bleeding ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | RR 0.1 [0.01, 1.94] | 1 study · 40 participants | Very low |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Quality of life ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Asymptomatic venous thromboembolism · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates Clinically relevant non‐major bleeding ‐ not reported · thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin First‐time symptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (2020) · Cochrane | no estimate extracted | 1 study · 224 participants | Ungraded |
Physical exercise vs no physical exercise Mortality · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | RR 1.1 [0.79, 1.52] | 6 studies · 1172 participants | Low |
Physical exercise vs no physical exercise Quality of Life Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | SMD 0.11 | 8 studies · 1259 participants | Low |
Physical exercise vs no physical exercise Physical functioning/QoL Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | SMD 0.15 | 8 studies · 1329 participants | Low |
Physical exercise vs no physical exercise Depression/QoL Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | SMD 0.19 | 6 studies · 445 participants | Low |
Physical exercise vs no physical exercise Anxiety/QoL Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | SMD 0.03 | 6 studies · 445 participants | Very low |
Physical exercise vs no physical exercise Fatigue Scale from: ‐1 to 1 with 1 indicating best outcome · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | SMD 0.31 | 9 studies · 826 participants | Moderate |
Physical exercise vs no physical exercise Serious adverse events · Adults with haematological malignancies Aerobic physical exercise for adult patients with haematological malignancies (2019) · Cochrane | RR 1.39 [0.94, 2.06] | 6 studies · 435 participants | Very low |